Atai Life Sciences (ATAI): Assessing Valuation After a Sharp Rebound in 2024 Returns

Atai Beckley (ATAI) has quietly turned heads with a sharp year to date rebound, even as recent month and past 3 months returns cooled. Investors are asking whether this reset offers a fresh entry point.

See our latest analysis for Atai Beckley.

The latest 1 day share price return of 8.37 percent and 7 day gain of 17.33 percent come after a choppy stretch, with a 30 day share price return of negative 16.67 percent and a still impressive 175 percent year to date share price return, alongside a 195.3 percent 1 year total shareholder return. This suggests momentum has cooled but the long term rebound story is intact.

If this kind of sharp rebound in a higher risk biotech name has your attention, it may be worth exploring pharma stocks with solid dividends as potential steadier income opportunities in the same space.

With revenue growth accelerating, but losses still deep and the share price far below analyst targets, the key question is whether Atai Beckley remains mispriced value or if the market is already discounting its pipeline success and future growth potential.

Price to Book of 10 times, is it justified?

Atai Beckley trades on a price to book ratio of around 10 times, which leaves the stock looking expensive versus both peers and the wider US pharmaceuticals sector at the latest close of $4.40.

The price to book multiple compares the market value of the company to the accounting value of its net assets. This is a common yardstick for early stage biotechs that lack meaningful earnings. In Atai Beckley’s case, paying 10 times book value implies investors are assigning a substantial premium to the pipeline and future optionality rather than the current balance sheet.

However, the company remains unprofitable, generates only around 3 million dollars of revenue, and is not forecast to achieve profitability over the next three years, so this premium looks demanding. Against an industry and peer average of roughly 2.5 times book, the current valuation suggests the market is pricing in significantly stronger outcomes than the sector norm, despite similar or higher risk.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book of 10 times (OVERVALUED)

However, looming clinical trial setbacks or prolonged unprofitability could quickly puncture sentiment, forcing investors to reassess how much future success is already reflected in the price.

Find out about the key risks to this Atai Beckley narrative.

Build Your Own Atai Beckley Narrative

If you see the story differently, or simply want to dig into the numbers yourself, you can shape a personalized view in minutes: Do it your way.

A great starting point for your Atai Beckley research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Do not stop with a single biotech. Use the Simply Wall Street Screener to uncover targeted opportunities that match your strategy before the market catches on.

• Target higher potential total returns by focusing on income and growth from these 15 dividend stocks with yields > 3% that can strengthen your portfolio’s cash flow.
• Catch the next wave of innovation early by focusing on these 26 AI penny stocks positioned at the heart of the artificial intelligence boom.
• Strengthen your risk reward profile by hunting for mispriced companies within these 908 undervalued stocks based on cash flows that may be trading below their intrinsic value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com